Dr Srour on Next Steps Planned for the Investigation of ALLO-316 in Advanced Clear Cell RCC
June 2nd 2023Samer A. Srour, MB ChB, MS, discusses planned next steps and future avenues of investigation for the novel CD70-targeted agent ALLO-316 in patients with advanced or metastatic clear cell renal cell carcinoma.
Read More
Dr Srour on the Mechanism of Action of ALLO-316 in Metastatic Clear Cell RCC
May 22nd 2023Samer A. Srour, MB ChB, MS, discusses the mechanism of action of ALLO-316, which is being investigated for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma, and details safety findings from the phase 1 TRAVERSE study evaluating ALLO-316 in this patient population.
Read More
Dr. Srour on Orca-Q Transplantation in Hematologic Malignancies
February 18th 2023Samer A. Srour, MB ChB, MS, discusses findings with Orca-Q, an investigational therapy consisting of enriched CD34+ stem cells plus T-cell subsets, in patients with high-risk hematologic malignancies eligible for myeloablative conditioning and allogeneic stem cell transplant.
Read More